New Study shows that Psoriasis Treatment Injection linked To Multiple Cancers
WASHINGTON, DC—in New Study Researchers scrutinizing the adverse reporting data of the FDA suggest ustekinumab (Stelara), a mainstay of new psoriasis treatment, may be related to multiple cancers.In a poster presentation at the 74th annual meeting of the American Academy of Dermatology, Aleksandra Florek, MD, Dermatology Clinical Research Fellow at the Feinberg School of Medicine at Northwestern University, Chicago, said, “Safety signals from the FDA Adverse Event Reporting System (FAERS) database suggest that ustekinumab drug for Psoriasis Treatment is associated with several malignancies not recognized in the Full Prescribing Information.“
Further long-term, prospective clinical trials and larger epidemiologic pharmaceutical studies are necessary to more precisely quantify the cancer risk that is associated with ustekinumab,” she continued.
New Study Of Psoriasis Treatment Drug Methodology
Florek and her colleagues, in reviewing nearly 5,000 adverse reports submitted to the FAERS database, detected safety signals that linked ustekinumab to B-cell lymphoma, epithelioid sarcoma, lung cancer, esophageal cancer, ovarian cancer, renal cancer, testicular cancer, and thyroid cancer.